Pfizer (FRA:PFE) Total Liabilities : €125,824 Mil (As of Dec. 2023)

View and export this data going back to 1951. Start your Free Trial

What is Pfizer Total Liabilities?

Pfizer's Total Liabilities for the quarter that ended in Dec. 2023 was €125,824 Mil.

Pfizer's quarterly Total Liabilities declined from Jun. 2023 (€111,567.63 Mil) to Sep. 2023 (€110,394.53 Mil) but then increased from Sep. 2023 (€110,394.53 Mil) to Dec. 2023 (€125,824.32 Mil).

Pfizer's annual Total Liabilities increased from Dec. 2021 (€92,052.39 Mil) to Dec. 2022 (€95,616.82 Mil) and increased from Dec. 2022 (€95,616.82 Mil) to Dec. 2023 (€125,824.32 Mil).

Pfizer Total Liabilities Historical Data

The historical data trend for Pfizer's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Total Liabilities Chart

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

93,732.30

74,601.43

92,052.39

95,616.82

125,824.32

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															95,616.82	88,151.85	111,567.63	110,394.53	125,824.32

Pfizer Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pfizer's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	43827.098	+	(55477.583	+	23945.621
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	586.88	+	1987.139)
	=	125,824

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	207701.417	-	81877.096
	=	125,824

Pfizer's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	43827.098	+	(55477.583	+	23945.621
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	586.88	+	1987.139)
	=	125,824

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	207701.417	-	81877.096
	=	125,824

Pfizer Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pfizer's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (FRA:PFE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (FRA:PFE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PFE:USA PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.